News & Updates
Showing Pharmacy articles
Showing
Long-term risankizumab safe, effective in moderate-to-severe plaque psoriasis
Treatment with risankizumab in the long term shows lasting efficacy against moderate-to-severe plaque psoriasis and has good tolerability, according to the LIMMitless study.
Long-term risankizumab safe, effective in moderate-to-severe plaque psoriasis
20 Dec 2023
Add-on ribociclib continues to triumph in early breast cancer
Coming on the heels of the second interim analysis, the protocol-specified final invasive disease-free survival (iDFS) analysis of the phase III NATALEE trial continues to show a highly significant iDFS benefit with the combination of the CDK 4/6 inhibitor ribociclib and a nonsteroidal aromatase inhibitor (NSAI) in individuals with HR+/HER2- early breast cancer.
Add-on ribociclib continues to triumph in early breast cancer
20 Dec 2023
Most HF patients do not undergo loop diuretic dose reduction after SGLT2i initiation
Majority of the patients with heart failure (HF) who have initiated treatment with sodium-glucose cotransporter 2 inhibitor (SGLT2i) show no change in loop diuretic dose, reports a study.
Most HF patients do not undergo loop diuretic dose reduction after SGLT2i initiation
19 Dec 2023
What prevents patients from receiving a COVID-19 vaccine?
A recent study has found potential associations between vaccine hesitancy and epidemiologic factors, including barriers to receiving vaccination against COVID-19.
What prevents patients from receiving a COVID-19 vaccine?
18 Dec 2023
Second-line CAR-T too costly for treatment of diffuse large B-cell lymphoma
Second-line treatment with axicabtagene ciloleucel (axi-cel) or lisocabtagene maraleucel (liso-cel) helps improve survival in high-risk patients with diffuse large B-cell lymphoma (DLBCL), but both therapies are expensive, a study has shown.